HEXA Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung carcinoma epithelial line. The cells carry heterogeneous loss-of-function disruptions in the HEXA gene, allowing study of target gene deficiency without clonal bias. This mixed population preserves genetic diversity while ablating HEXA function, providing a reliable model for investigating the collective effects of GM2 ganglioside catabolism defects in a well-characterized cancer background.
The A-549 cell line, originally isolated from lung adenocarcinoma tissue, displays characteristics of alveolar type II pneumocytes and is widely used to study lung adenocarcinoma biology, including tumor progression, drug resistance, and epithelial?Cmesenchymal transition. Its adherent epithelial morphology and robust growth make it a versatile platform for examining lysosomal metabolism in the context of pulmonary cancer.
HEXA encodes the ??-subunit of ??-hexosaminidase A, a lysosomal enzyme that, together with the ??-subunit (HEXB) and the GM2 activator protein (GM2A), hydrolyzes terminal N-acetyl-D-galactosamine residues from GM2 ganglioside. This reaction is required for ganglioside degradation, yielding GM3 and ceramide. HEXA expression is regulated by TFEB, and its activity is modulated by lysosomal pH and substrate accumulation. Interacting partners include GM2A, HEXB, and the sphingolipid activator SAP-B. Loss of HEXA function disrupts glycosphingolipid metabolism, leading to lysosomal GM2 accumulation, which is central to Tay-Sachs disease and GM2 gangliosidoses.
In A-549 cells, HEXA knockout enables investigation of glycosphingolipid dysregulation in lung adenocarcinoma. Altered ganglioside profiles are implicated in cancer cell proliferation, migration, and immune evasion. While HEXA deficiency is canonically associated with neurodegeneration, this model permits dissection of GM2 accumulation effects on oncogenic signaling and lysosomal function in a non-neuronal context, bridging lysosomal storage disorder pathology and tumor biology.
Applications include Tay-Sachs disease modeling, pharmacological chaperone screening, and gene therapy evaluation. Quantitative GM2 accumulation assays (HPLC/MS), enzymatic activity measurements with fluorogenic substrates, and lysosomal imaging (LysoTracker, IF) are readily performed. For cancer studies, migration/invasion assays and glycolipid signaling analyses exploit the polyclonal model??s robustness. Contact Ascent Research for additional technical information.
